jrnls.org logo
Submit

BROWSE ALL JOURNALS

SEE ALL 19 JOURNALS
Journal of Pharmacology and PharmacotherapeuticsNOW IN
Article

A new drug belonging to a novel class of drugs for type 2 diabetes

Sivagnanam G1★★ Corresponding author

  1. 1Department of Pharmacology, Indira Gandhi Medical College and Research Institute, Kadhirkamam, Puducherry, India.

CORRESPONDENCE

Sivagnanam G

Department of Pharmacology, Indira Gandhi Medical College and Research Institute, Kadhirkamam, Puducherry, India.

drsivagnanam@gmail.com

Volume 4, Issue 3 · pp. 224–224 · PUBLISHED 2013 · DOI: 10.4103/0976-500X.114621

View on JPP original site ↗

ABSTRACT

The FDA approval of canagliflozin (Invokana) was based on data involving over 10,285 type 2 diabetes patients, which showed improvement in hemoglobin A1c and fasting plasma glucose levels. Canagliflozin has been tested as monotherapy as well as in combination with metformin, sulphonylurea, pioglitazone, and insulin

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    G, S. (2013). A new drug belonging to a novel class of drugs for type 2 diabetes. Journal of Pharmacology and Pharmacotherapeutics, 4(3), 224–224. https://doi.org/10.4103/0976-500X.114621